TNF-alpha

Assets acting on this target.

Class
Anti-TNF inhibitor
Pathway
TNF-α signalling

Tumor necrosis factor-alpha (TNF-α) is a signaling protein, or cytokine, produced mainly by immune cells such as macrophages and T cells during inflammation. Under normal conditions it helps coordinate short-term immune defenses, recruiting other immune cells and inducing fever and tissue changes needed to fight infection or injury. In chronic inflammatory diseases, however, TNF-α is produced persistently and in excess, driving ongoing tissue damage. This is well documented in rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, where TNF-α perpetuates joint erosion, skin plaque formation, or intestinal ulceration. Blocking TNF-α, either by neutralizing the free cytokine or preventing it from engaging its cell-surface receptors, interrupts this self-sustaining inflammatory cycle and can substantially reduce disease activity across these conditions. This rationale has made TNF-α one of the most extensively targeted pathways in immunology, drugged by monoclonal antibodies, antibody fragments, fusion proteins, and increasingly small molecules. Some newer approaches pair TNF-α blockade with inhibition of a second inflammatory mediator, such as interleukin-17 or interleukin-23, reflecting the observation that several cytokine pathways often act together to sustain chronic inflammation, and that addressing more than one simultaneously may produce broader control than blocking TNF-α alone.

By indication

Related mechanisms

TNF-alpha drugs compared

23 drugs, stage by indication
23 drugs acting on TNF-alpha: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
adalimumabHumiraAbbViemonoclonal antibody (fully human IgG1)ApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-aacf (Idacio)IdacioFresenius SE & Co. KGaAmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-aaty (Yuflyma)YuflymaCelltrionmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-adaz (Hyrimoz)HyrimozCordavis, Sandoz Group AGmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-adbm (Cyltezo)CyltezoBoehringer Ingelheimmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-afzb (Abrilada)AbriladaPfizermonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-aqvh (Yusimry)YusimryHong Kong King-Friend Industrial Co., Ltd., Meitheal Pharmaceuticalsmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-atto (Amjevita)AmjevitaAmgenmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-bwwd (Hadlima)HadlimaOrganon, Samsung Bioepismonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-fkjp (Hulio)HulioBioconmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
adalimumab-ryvk (Simlandi)SimlandiAlvotech, Teva Pharmaceutical Industriesmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
certolizumab pegolCimziaUCBPEGylated anti-TNF Fab' fragmentApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis
etanerceptEnbrelAmgen, Pfizerfusion proteinApprovedApproved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis
golimumabSimponiJohnson & Johnsonmonoclonal antibody (fully human IgG1)ApprovedApproved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis; Phase 2 in Crohn's Disease
infliximabRemicadeJohnson & Johnsonmonoclonal antibody (chimeric IgG1)ApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
infliximab-abda (Renflexis)RenflexisOrganon, Samsung Bioepismonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
infliximab-axxq (Avsola)AvsolaAmgenmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
infliximab-dyyb (Inflectra)InflectraCelltrion, Pfizermonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
infliximab-dyyb (Zymfentra)ZymfentraCelltrionmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Ulcerative Colitis
infliximab-qbtx (Ixifi)IxifiPfizermonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis
JNJ-78934804Johnson & JohnsonCo-antibody combination (guselkumab + golimumab, SC)Phase 3Phase 3 in Crohn's Disease; Phase 3 in Ulcerative Colitis
Hemay007Tianjin Hemay Pharmaceuticalsmall moleculePhase 1Phase 1 in Crohn's Disease
SOR102Sorriso PharmaceuticalsBiologic (oral dual TNFα/IL-23(p19) inhibitor)Phase 1Phase 1 in Ulcerative Colitis

← all mechanisms